STOCKS TELEGRAPH

Tag: VBI Vaccines

  • VBI Vaccines Inc. (VBIV) Stock Dips Despite Promising Data from Covid-19 Vaccine Trial

    VBI Vaccines Inc. (VBIV) Stock Dips Despite Promising Data from Covid-19 Vaccine Trial

    VBI Vaccines Inc. (VBIV) stock prices were down by 8.5586% some time after market trading commenced on June 29th 2021, bringing the price up to USD$3.6668 earlier on in the trading day.

    Positive Trial Data

    The company announced on June 29th the positive Phase 1 data from its Phase 1/2 of its Covid-19 vaccine candidate, VBI-2902a. The trial saw the administering of the enveloped virus-like particle (eVLP) in healthy adults between the ages of 18 and 54. The 5µg dose expressed an optimized Covid-19 spike antigen, having been adjuvanted with aluminum phosphate.

    Trial Results

    It was generally well-tolerated and exhibited potent immune responses from subjects that were significantly higher than those seen in human convalescent sera. The potency of the eVLP particulate delivery platform against Covid-19 was demonstrated with the findings establishing a robust human proof-of-concept at a low dose and without the use of a next-generation adjuvant.

    Developing eVLPs

    The highly encouraging data furthers the development of the treatment that is being pushed towards commercialization with the support of the Canadian government, CEPI, and the National Research Council of Canada. The next phase of the ongoing adaptive Phase 1/2 study involved the assessment of VBI-2905a, with the commencement of this part of the trial anticipated for the third quarter of 2021.The company is also allocating resources towards developing multivalent eVLP candidates, which are designed to increase the scope of protection against Covid-19. A clinical study of one of these candidates is expected to commence in the first half of 2022.

    Details of the Trial

    The ongoing adaptive Phase 1/2 clinical study is randomized and placebo-controlled, with observers also being blind. Phase 1 assessed a 5µg dose of VBI-2902a, adjuvanted with aluminum phosphate. Treatment regimens included both one and two doses, with the second being administered 28 days after the initial jab. The Phase 1 part of the study saw a total of 61 healthy adults between the ages of 18 and 54, with no history of having been vaccinated against Covid-19.

    Future Outlook for VBIV

    With the world hurtling towards universal immunizations, VBIV is poised to continue its trajectory of success. The company is keen to usher in further growth as it continues to push for increased market penetration. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value

  • Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    As the U.S. reached 300,000 deaths connected with Covid-19, the first shots were given. The nurse in New York City was first vaccinated against COVID-19. On Monday, during the American mass vaccine drive, the first shot was rendered, which opened a new chapter in the fight against coronavirus’s pandemic.

    This week’s total number of shipments could exceed 2.9 million doses of Pfizer vaccine, which the FDA approved last Friday night for emergency use. A further 2.9 million supplies are eligible three weeks from now for recipients to receive a second dose.

    Phase 3 clinical trials found that the vaccine is 95 percent successful over a spectrum of age, ethnic and racial groups when administered in two doses. The first vaccination this week is obtained by front-line community staff and others who work with long-term care.

    BioCardia Inc. (NASDAQ:BCDA) shares were trading up 58.87% at $4.48 at the time of writing on Monday following the company reported that it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules.

    BioCardia Inc. (NASDAQ:BCDA) share price went from a low point around $1.91 to briefly over $6.75 in past 52 weeks, though shares have since pulled back to $4.48. BCDA market cap has remained high, hitting $60.84M at the time of writing, giving it price-to-sales ratio of more than 200.

    Rubius Therapeutics Inc. (RUBY) last closed at $8.73, in a 52-week range of $3.35 to $14.44. Analysts have a consensus price target of $10.67.

    AnPac Bio-Medical Science Co. Ltd. (ANPC) stock soar by 35.07% to $5.70 after reporting that it has made significant progress in detecting pre-cancer diseases.

    Synlogic Inc. (NASDAQ:SYBX) Shares headed rising, higher as much as 13.39% following the announcement of advancement of SYNB1891 to combination arm dosing with PD-L1 checkpoint inhibitor in the on-going phase 1 study for the treatment of solid tumors and lymphoma. The most recent rating by Oppenheimer, on August 21, 2019, is at a Perform.

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 29.20% after gaining more than $35.33 on Monday.

    Arbutus Biopharma Corporation (ABUS) last closed at $4.88, in a 52-week range of $0.88 to $9.02. Analysts have a consensus price target of $6.40.

    Amarin Corporation plc (AMRN) stock soar by 1.60% to $5.09 after announcing the presentation of important VASCEPA® (icosapent ethyl)-related scientific findings during the National Lipid Association (NLA) Scientific Sessions 2020. The most recent rating by JP Morgan, on September 29, 2020, is at a Neutral.

    Arvinas Inc. (NASDAQ:ARVN) Shares headed rising, higher as much as 95.06% after revealing that it is commencing an underwritten public offering of $250.0 million of its common stock. The most recent rating by Oppenheimer, on December 14, 2020, is at an Outperform.

    BioLineRx Ltd. (NASDAQ:BLRX) rose 26.97% after gaining more than $0.72 on Monday. The company on November 23, 2020 reported its financial results for the quarter ended September 30, 2020.

    Homology Medicines Inc. (FIXX) last closed at $11.97, in a 52-week range of $8.70 to $22.50.

    BioCryst Pharmaceuticals Inc. (BCRX) stock soar by 4.68% to $8.50. The firm is presenting at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m. ET. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight.

    BioNTech SE (NASDAQ:BNTX) Shares headed falling, lower as much as -14.95% after the company and Pfizer Inc. (PFE) declared additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The most recent rating by BofA Securities, on December 01, 2020, is at a Neutral.

    Akebia Therapeutics Inc. (NASDAQ:AKBA) rose 10.80% after gaining more than $0.31 on Monday. The firm reported the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community.

    Seelos Therapeutics Inc. (SEEL) last closed at $1.28, in a 52-week range of $0.42 to $1.71 after announcing the sale of a $12.0 million senior secured convertible note and shares of Seelos common stock to investors.

    VBI Vaccines Inc. (VBIV) stock soar by 6.71% to $3.34. The company recently revealed a partnership for the commercialization of VBI’s 3-antigen prophylactic hepatitis B (HBV) vaccine in the United States, Europe, and Canada, pending regulatory approvals. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy.

  • Pre-Market Cues: 32 Stocks Roaring for Change On December 1st

    Pre-Market Cues: 32 Stocks Roaring for Change On December 1st

    China Automotive Systems Inc. (CAAS) stock soared 2.38% to $10.75 in the pre-market trading after reporting that it shipped approximately 120,000 units from its portfolio of electric power steering products for use in Chinese electric vehicles during 2020. The most recent rating by Brean Murray, on August 15, 2011, is a Hold.
    Before the trading started on December 01, 2020, G1 Therapeutics Inc. (GTHX) is up 4.05% to reach $19.0. It has been trading in a 52-week range of $8.80 to $31.38.
    Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 29.83% at $0.947 at the time of writing following the announcement its elimination of senior secured second lien convertible notes. Company’s 52-week ranged between $0.14 to $3.88.
    Jaguar Health Inc. (JAGX) grew over 69.45% at $0.5929 in pre-market trading today.
    SuperCom Ltd. (SPCB) stock moved down -10.74 percent to $1.08 in the pre-market trading and the company recently declared that it has secured a contract to provide its PureSecurity Electronic Monitoring (EM) suite in Wisconsin.
    MicroStrategy Incorporated (NASDAQ: MSTR) shares are trading up 4.93% at $359.66 at the time of writing. Company’s 52-week ranged between $90.00 to $280.00. Analysts have a consensus price target of $200.
    Veritone Inc. (VERI) grew over 4.4% at $27.78 in pre-market trading today after announcing that it now supports NVIDIA CUDA for GPU-based AI and machine learning.
    Before the trading started on December 01, 2020, Creative Realities Inc. (CREX) is down -7.26% to reach $1.15. It has been trading in a 52-week range of $0.52 to $5.98.
    Moderna Inc. (MRNA) stock soared 10.32% to $168.5 in the pre-market trading after declaring that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The most recent rating by Wells Fargo, on November 23, 2020, is an Equal weight.
    VBI Vaccines Inc. (VBIV), a Biotechnology company, rose about 3.94% at $3.56 in pre-market trading Tuesday.
    Schultze Special Purpose Acquisition Corp. (SAMA) stock moved up 2.86 percent to $12.6 in the pre-market trading after reporting effectiveness of registration statement for proposed business combination with Clever Leaves International Inc.
    Celsion Corporation (CLSN) gained over 5.59% at $0.71 in pre-market trading Tuesday December 01, 2020.
    Nano-X Imaging Ltd. (NNOX) is up more than 5.22% at $64.5 in pre-market hours Tuesday December 01, 2020. The healthcare firm lately announced revised time of live demonstration at the 2020 radiology society of North America virtual annual meeting. The stock had jumped over 17.21% to $61.30 in the last trading session.
    Before the trading started on December 01, 2020, Greenlane Holdings Inc. (GNLN) is up 2.89% to reach $4.27. It has been trading in a 52-week range of $1.02 to $4.20.
    Mogo Inc. (MOGO) stock soared 3.77% to $2.75 in the pre-market trading. The firm recently declared the release of its new updated Mogo app featuring an interactive Rainforest Mode as part of the MogoCard experience. The most recent rating by Raymond James, on July 23, 2020, is an Outperform.
    Altimmune Inc. (NASDAQ: ALT) shares are trading up 9.57% at $13.4 at the time of writing. Company’s 52-week ranged between $1.60 to $35.10. Analysts have a consensus price target of $28.
    Novavax Inc. (NVAX) grew over 6.09% at $148.0 in pre-market trading today following publication its COVID-19 vaccine clinical development progress.
    Marathon Patent Group Inc. (MARA), a Capital Markets company, rose about 7.96% at $6.78 in pre-market trading Tuesday.
    Aphria Inc. (APHA) is up more than 3.46% at $8.67 in pre-market hours Tuesday December 01, 2020. The healthcare company recently revealed that it has closed the accretive, strategic acquisition of SW Brewing Company, LLC. The stock had jumped over 8.41% to $8.38 in the last trading session.
    AquaBounty Technologies Inc. (AQB) gained over 4.31% at $6.05 in pre-market trading Tuesday December 01, 2020.
    Before the trading started on December 01, 2020, ADMA Biologics Inc. (ADMA) is up 2.45% to reach $2.09 following the announcement its commencement of operations and initiation of collections at its newest ADMA BioCenters plasma collection facility located in Maryville, Tennessee. It has been trading in a 52-week range of $1.45 to $4.95.
    CureVac N.V. (CVAC) is down more than -3.12% at $101.89 in pre-market hours Tuesday December 01, 2020. The stock had jumped over 22.29% to $105.17 in the last trading session.
    OrganiGram Holdings Inc. (OGI) gained over 4.26% at $1.47 in pre-market trading Tuesday December 01, 2020 after releasing its results for the fourth quarter ended August 31, 2020.
    FuelCell Energy Inc. (FCEL) is down more than -3.43% at $9.85 in pre-market hours Tuesday December 01, 2020. The stock had jumped over 5.26% to $10.20 in the last trading session.
    SSR Mining Inc. (SSRM) grew over 2.12% at $18.8 in pre-market trading today. The company lately publicized that positive results of the Çöpler District master plan studies.
    Before the trading started on December 01, 2020, Entasis Therapeutics Holdings Inc. (ETTX) is up 4.35% to reach $1.92. It has been trading in a 52-week range of $1.58 to $5.64.
    Luokung Technology Corp. (LKCO) is up more than 2.93% at $0.6 in pre-market hours Tuesday December 01, 2020 after the firm reported that it won bid for Heilongjiang Institute of Technology (“HIT”) Smart Campus first phase procurement project of USD 1.3 million. The stock had jumped over 4.09% to $0.58 in the last trading session.
    Riot Blockchain Inc. (RIOT) is up more than 3.55% at $8.75 in pre-market hours Tuesday December 01, 2020. The stock had jumped over 35.20% to $8.45 in the last trading session.
    Before the trading started on December 01, 2020, Dada Nexus Limited (DADA) is down -4.28% to reach $55.47 after declaring proposed follow-on public offering of American depositary shares. It has been trading in a 52-week range of $14.60 to $56.91.
    Logitech International S.A. (NASDAQ: LOGI) shares are trading down -3.3% at $87.32 at the time of writing. Company’s 52-week ranged between $31.37 to $95.71.
    Advaxis Inc. (ADXS), a Biotechnology company, rose about 11.86% at $0.33 in pre-market trading Tuesday. The biotechnology firm recently declared closing of $9.2 million public offering.
    Arbutus Biopharma Corporation (NASDAQ: ABUS) shares are trading up 11.26% at $5.04 at the time of writing. Company’s 52-week ranged between $0.88 to $9.02. Analysts have a consensus price target of $8.